Market Dynamics: The global market for Alagille syndrome is poised to exhibit a stable growth in revenue over the forecast period. Several factors are fueling the expansion of revenue in the global Alagille syndrome market, with one of the primary drivers being the increasing incidence of the disease. According to the National Organization for Rare Disease (NORD), the worldwide incidence of Alagille syndrome is estimated to be one patient in every 30,000 to 45,000 of the population.
Alagille syndrome is a rare genetic disorder that can affect various organs in the body, including the bones, eyes, liver, heart, kidneys, and other vital organs. Additionally, the presence of an abnormally low number of tiny bile ducts in the liver contributes to liver-related issues, leading to the accumulation of bile inside the liver, causing damage and scarring. This syndrome is known by various names, such as Alagille-Watson syndrome, Arteriohepatic Dysplasia (AHD), cardiovertebral syndrome, or syndromic bile duct paucity.
Get a sample copy of the Alagille Syndrome Market report: https://www.reportsanddata.com/download-free-sample/5633
Factors contributing to revenue growth in the market include: Drivers: The foremost factors responsible for the growth of the Alagille syndrome market include the increasing prevalence of this genetic disorder worldwide and the rising number of patients with liver cancer. In 2020, there were approximately 900,000 new cases of liver cancer reported worldwide. Furthermore, the escalation of research and development (R&D) activities aimed at developing novel therapeutics for Alagille syndrome treatment and increased government investments in healthcare infrastructure and facilities are expected to drive revenue growth in the global Alagille syndrome treatment market.
Restraints: Unfavorable reimbursement policies in developing and underdeveloped countries, as well as a lack of awareness among the public regarding the syndrome and its associated treatments, are anticipated to hinder revenue growth in the market. Additionally, the shortage of skilled medical professionals in certain regions is a key factor expected to restrain revenue growth in the global Alagille syndrome treatment market.
Geographic Market Scenario: Largest Market Share: North America is projected to account for the largest share of revenue in the global Alagille syndrome market due to the increasing prevalence of this rare disease and related cancer disorders in the region. The presence of major players, such as Mirum Pharmaceuticals and Albireo Pharma, Inc., in the region is driving revenue growth. Moreover, a well-developed healthcare infrastructure, facilities, and an upsurge in R&D activities for novel medications for Alagille syndrome treatment contribute to the market’s revenue growth.
Fastest Growing Region: The Asia Pacific market is expected to register a steady growth in revenue with a compounded annual growth rate (CAGR) over the forecast period due to the increasing prevalence of Alagille syndrome and a rising number of cancer patients in the region. Additionally, increased government spending on healthcare infrastructure and facilities, along with investments in initiatives and campaigns to raise awareness about rare diseases and their treatment, is expected to drive revenue growth in the region.
What Our Report Provides and Why Our Offering Is Superior: This report provides historical data, forecasts, and revenue growth trends at the global, regional, and country levels. It offers detailed analysis of industry trends, consumption patterns, and industry strategies for each region, major country, and segment from 2019 to 2030. The global market report covers industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and revenue share contribution by each regional and country market. Furthermore, the report includes industry analysis, competitive landscape, company financials, and impact analysis.
Key Market Trends and Innovations: Drug: Odevixibat – Albireo is conducting long-term safety and efficacy research on Odevixibat in patients with Alagille Syndrome. Currently, this research is in phase 3 of clinical trials and is expected to be completed by October 2023.
Organic and Inorganic Strategies Adopted: In February 2022, CANbridge Pharmaceuticals, Inc. announced the approval of CAN108 (maralixibat), a drug used for the treatment of Alagille Syndrome (ALGS), by the National Medical Products Administration (NMPA) of China. In September 2021, Mirum Pharmaceuticals, Inc., a leader in rare liver diseases, received approval from the U.S. Food and Drug Administration (FDA) for the LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS) in patients one year of age and older.
Major Companies in the Market Include:
- Teva Pharmaceutical Industries Ltd.
- AbbVie Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals Inc.
- Mylan Pharmaceuticals Inc.
- Sanofi S.A.
- Novartis International AG
- Akorn Inc.
- Albireo Pharma Inc.
- Mirum Pharmaceuticals
Start-ups: No relevant start-ups related to the market were identified.
Scope of the Alagille Syndrome Market: Medication Outlook (Revenue, USD Billion; 2019-2030)
- Ursodeoxycholic Acid
- Cholestyramine
- Rifampin
- Naltrexone
- Anti-histamine
Product Type Outlook (Revenue, USD Billion; 2019-2030)
- Tablet
- IV/injections
Route of Administration Outlook (Revenue, USD Billion; 2019-2030)
- Oral
- Parenteral
Distribution Channels Outlook (Revenue, USD Billion; 2019-2030)
- Online
- Offline
End-user Outlook (Revenue, USD Billion; 2019-2030)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Regional Outlook (Revenue, USD Billion; 2019-2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Sweden
- BENELUX
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest of MEA
Explore Trending Reports:
Prebiotic Ingredients Market-https://www.globenewswire.com/news-release/2019/10/16/1930796/0/en/Prebiotic-Ingredients-Market-To-Reach-USD-8-34-Billion-By-2026-Reports-And-Data.html
Artificial Flavors Market-https://www.globenewswire.com/news-release/2020/03/10/1998277/0/en/Artificial-Flavors-Market-To-Reach-USD-15-20-Billion-By-2027-Reports-and-Data.html
Plasma Etch System Market-https://www.globenewswire.com/news-release/2019/03/25/1760466/0/en/Plasma-Etch-System-Market-to-Reach-USD-8-7-Billion-By-2026-Reports-And-Data.html
Industrial Analytics Market-https://www.globenewswire.com/news-release/2019/09/26/1921416/0/en/Industrial-Analytics-Market-To-Reach-USD-47-46-Billion-By-2026-Reports-And-Data.html
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5633
Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press Release: https://www.reportsanddata.com/press-release